Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
TERPS
TERPS Trial for de Novo Oligometastic Prostate Cancer
- NCT05223803 ↗
- Recruiting
- University of Maryland, Baltimore
- Focused
We haven't built an HCP commentary report on TERPS (systemic therapy in Prostate Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on TERPS so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 9 |
The trial
ClinicalTrials.gov- Official title
- Phase 2 Randomized Total Eradication of Metastatic Lesions Following Definitive Radiation to the Prostate in de Novo oligometaStatic Prostate Cancer (TERPS) Trial
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Prostate Cancer; Oligometastatic Disease
- Interventions
- Prostate radiation (XRT); Systemic Therapy; Stereotactic ablative radiation therapy (SABR)
- Arms
- Best systemic therapy (BST) + primary prostate radiation (XRT) · Active comparator
- BST + XRT + SABR metastasis-directed therapy (MDT) · Active comparator
- Enrollment
- 122 (estimated)
- Primary outcomes
- To determine the 2-year failure-free survival (FFS) of men who have oligometastatic prostate cancer with BST+XRT versus BST+XRT+SABR MDT.
- Sponsor
- University of Maryland, Baltimore
- Start
- Oct 18, 2022
- Primary completion
- Jul 31, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT05223803 · updated Jun 3, 2026